This core supports Projects 1 ? 3 by collecting long-term follow-up data for patients who have had hematopoietic cell transplantation (HCT) or genetically modified T cell therapy at the Seattle Cancer Care Alliance (SCCA), University of Washington (UW) or Seattle Children's Hospital (SCH) under protocols developed at the Fred Hutchinson Cancer Research Center (FHCRC). The services of this core unit address several closely related areas: identification and management of late complications, data and research sample collection, database assembly and evaluation of the efficiency, accuracy, quality and utility of the data collection and the system in which the data are stored. We have developed several mechanisms to support this overall goal. 1. We will collect long-term data focused on survival, therapy-related complications, and health relevant to the clinical research studies sponsored by this grant. This includes the prospective cohort of patients to be enrolled in studies described in Projects 1 ? 3 of this grant application, some of whom will be receiving genetically modified cells and thus follow-up for at least 15 years after treatment is recommended. For this purpose, a system has been established to track and maintain contact with patients and referring physicians so that data can be collected at specified time points after treatment. 2. We will assist investigators in obtaining information and research biospecimens that are not routinely collected but are needed for individual research projects. 3. We will continue to identify barriers that interfere with long-term follow-up of geographically dispersed patients and develop methods to overcome these barriers. 4. We will continue to evaluate the research methods employed in data collection and database management, including the efficiency, reliability, validity and utility of the instruments used for data collection. The data generated from this core unit will assist project leaders in understanding the long-term efficacy of experimental treatments and identifying late complications after cellular therapy with HCT or genetically modified T cells. Close coordination with the clinical Long-Term Follow-Up Program (LTFU) that provides telemedicine services ensures prompt notification of clinical events. Integrating long-term data collection efforts across the Projects through Core D provides efficient services to support this Research Program.

Public Health Relevance

The Long-Term Follow-Up Unit (LTFU, Core D) supports the Program by providing extended data collection and biospecimen acquisition services to the three Projects. Through a combination of chart review, annual surveys and active contact with participants and providers, Core D is responsible for ensuring that protocol requirements beyond the acute treatment phase (generally 2-3 months) are performed. Core D also interacts closely with Core B, which is responsible for early data collection and data analysis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA018029-42A1
Application #
9490723
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-04-01
Budget End
2019-03-31
Support Year
42
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
McCune, Jeannine S; Storer, Barry; Thomas, Sushma et al. (2018) Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients. Biol Blood Marrow Transplant 24:1802-1807
Deegan, Anthony J; Talebi-Liasi, Faezeh; Song, Shaozhen et al. (2018) Optical coherence tomography angiography of normal skin and inflammatory dermatologic conditions. Lasers Surg Med 50:183-193
Leger, Kasey J; Baker, K Scott; Cushing-Haugen, Kara L et al. (2018) Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation. Cancer 124:1507-1515
Schmitt, Michael W; Pritchard, Justin R; Leighow, Scott M et al. (2018) Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias. Clin Cancer Res 24:5321-5334
Shaw, Bronwen E; Syrjala, Karen L; Onstad, Lynn E et al. (2018) PROMIS measures can be used to assess symptoms and function in long-term hematopoietic cell transplantation survivors. Cancer 124:841-849
Jamani, Kareem; Onstad, Lynn E; Bar, Merav et al. (2018) Quality of Life of Caregivers of Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 24:2271-2276
Ogimi, Chikara; Xie, Hu; Leisenring, Wendy M et al. (2018) Initial High Viral Load Is Associated with Prolonged Shedding of Human Rhinovirus in Allogeneic Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 24:2160-2163
Salter, Alexander I; Pont, Margot J; Riddell, Stanley R (2018) Chimeric antigen receptor-modified T cells: CD19 and the road beyond. Blood 131:2621-2629
Lee, Stephanie J; Nguyen, Tam D; Onstad, Lynn et al. (2018) Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:555-562
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313

Showing the most recent 10 out of 1845 publications